Enliven Therapeutics jumped on strong ELVN-001 phase 1b CML data, but a rich valuation may cap upside. Click here to read an ...
In the phase 2 FASCINATION trial, researchers sought to improve the rate of major molecular response 4 in patients newly diagnosed with CML.
Most patients diagnosed with chronic-phase chronic myeloid leukemia (CP-CML) who achieved a deep molecular response on tyrosine kinase inhibitor (TKI) therapy were able to avoid relapse despite ...
InvestorsHub on MSN
Enliven shares advance on encouraging early data from CML treatment study
Shares of Enliven Therapeutics (NASDAQ:ELVN) climbed 7% on Thursday after the company released positive early results from a ...
With results from a head-to-head study comparing its newer chronic myeloid leukemia (CML) treatment Scemblix to its own standard-of-care tyrosine kinase inhibitor (TKI) Gleevec in newly diagnosed ...
Scemblix outperformed standard tyrosine kinase inhibitor treatment in patients with Philadelphia chromosome-positive chronic myeloid leukemia. Frontline Scemblix (asciminib) improved outcomes over ...
Investing.com -- Enliven Therapeutics (NASDAQ:ELVN) stock surged 7% Thursday after the biopharmaceutical company reported positive initial Phase 1b data for its chronic myeloid leukemia (CML) drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback